SCHEDULE 13G: Paradigm BioCapital Discloses 5.0% Passive Stake in Cogent Biosciences
Beneficial Ownership Disclosure
Paradigm BioCapital Advisors LP and its affiliates have reported a 5.0% beneficial ownership stake in Cogent Biosciences, Inc., signaling a passive investment.
Summary
- Paradigm BioCapital Advisors LP, along with its general partner Paradigm BioCapital Advisors GP LLC, and its managing member Senai Asefaw, M.D., have collectively reported beneficial ownership of 5,559,924 shares of Cogent Biosciences, Inc. Common Stock.
- This aggregate ownership represents 5.0% of Cogent Biosciences' outstanding Common Stock.
- Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 4,906,897 shares, which constitutes 4.4% of the class.
- The beneficial ownership is based on 110,461,729 shares of Common Stock outstanding as of November 8, 2024, as reported by Cogent Biosciences in its Form 10-Q filed on November 12, 2024.
- The filing indicates that the securities were acquired and are held for passive investment purposes, not for changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Industry Context
This filing represents a standard disclosure of a significant passive investment by an institutional fund in a biotechnology company. Such disclosures are common and reflect investment firms taking positions in publicly traded companies based on their investment strategies.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may be viewed positively as a vote of confidence, potentially increasing liquidity or stability in the stock.
Key Dates
| Date | Description |
|---|---|
| 2024-11-08 | Date as of which 110,461,729 shares of Common Stock were outstanding, as reported by the Issuer in its Form 10-Q. |
| 2024-11-12 | Date Cogent Biosciences, Inc. filed its Form 10-Q with the SEC. |
| 2025-02-05 | Date of event which required the filing of this Schedule 13G. |
| 2025-02-12 | Date the Schedule 13G was signed and filed. |
Keywords
Cogent Biosciences, Paradigm BioCapital Advisors, Schedule 13G, Beneficial Ownership, Passive Investment, Common Stock, SEC Filing, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.